Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Song

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Ejhaem|June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) databaseRayan Kaedbey, Donna Reece, Christopher P Venner, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
American Journal of Hematology|May 5, 2018
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaXavier Leleu, Tamas Masszi, Nizar J Bahlis, et al.
Gastrointestinal Endoscopy|June 25, 2023
Long-term outcomes following successful endoscopic treatment of T1 esophageal adenocarcinoma: a multicenter cohort studyAllon Kahn, Kevin Song, Lovekirat Dhaliwal, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
Blood|June 25, 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myelomaMing Han, Alli Murugesan, Nizar J Bahlis, et al.
Cytotherapy|May 31, 2024
Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell productsBo Angela Wan, Lorenzo Lindo, Yasser Abou Mourad, et al.
European Journal of Haematology|August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisRichard LeBlanc, Hira Mian, Donna Reece, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2024
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014Nizar J Bahlis, Christy Samaras, Donna Reece, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Ejhaem|June 19, 2024
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) databaseRayan Kaedbey, Donna Reece, Christopher P Venner, et al.
European Journal of Haematology|February 4, 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myelomaHannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
American Journal of Hematology|May 5, 2018
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaXavier Leleu, Tamas Masszi, Nizar J Bahlis, et al.
Gastrointestinal Endoscopy|June 25, 2023
Long-term outcomes following successful endoscopic treatment of T1 esophageal adenocarcinoma: a multicenter cohort studyAllon Kahn, Kevin Song, Lovekirat Dhaliwal, et al.
Ejhaem|December 5, 2022
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseArleigh McCurdy, Martha Louzada, Christopher P Venner, et al.
Cancer|November 14, 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphomaDaniel J Landsburg, Adam M Petrich, Jeremy S Abramson, et al.
Blood|June 25, 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myelomaMing Han, Alli Murugesan, Nizar J Bahlis, et al.
Cytotherapy|May 31, 2024
Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell productsBo Angela Wan, Lorenzo Lindo, Yasser Abou Mourad, et al.
European Journal of Haematology|August 13, 2023
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisRichard LeBlanc, Hira Mian, Donna Reece, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 5, 2024
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014Nizar J Bahlis, Christy Samaras, Donna Reece, et al.
Pageof 10